| Preface | |
| List of Contributors | |
| Progression and Regression of Atherosclerosis | |
| Regression of Human Aortic Fatty Streaks of Early Life | p. 1 |
| Risk Factors for Coronary Heart Disease | |
| Serum Cholesterol as a Risk Factor: Effects of Gender and Age | p. 9 |
| Influence of Atherogenic Lipoproteins on the Thrombotic Potential of Endothelial Cells | p. 15 |
| Plurimetabolic Syndrome or Syndrome X. Is it a Real Syndrome? | p. 23 |
| Molecular Biology of Apolipoproteins | |
| Three Liver-Enriched Transcription Factors: HNF-1, C/EBP, and Protein II are Required to Enhance Transcription of the Human Apolipoprotein B Gene | p. 29 |
| Structure-Function Relationships of Apolipoprotein B-100 | p. 45 |
| Contribution of Helix-Helix Interactions to the Stability of Apolipoprotein-Lipid Complexes | p. 49 |
| New Aspects of Lipoprotein Metabolism | |
| Oxidatively Modified LDL and Atherosclerosis | p. 57 |
| Postprandial Hyperlipidemia and Coronary Artery Disease | p. 69 |
| Genetic Factors Affecting Lipoprotein Metabolism | p. 75 |
| Lipoprotein Assembly: A Potential Target for Drugs Affecting Lipid Metabolism | p. 83 |
| Fatty Acid, Lipase and Triglyceride Metabolism | |
| Structural Features that Determine the Functional Properties of the Loop Region of Human Lipoprotein Lipase | p. 89 |
| Molecular Genetics of Lipoprotein Lipase Deficiency | p. 97 |
| A New Case of Lipoprotein Lipase Deficiency | p. 101 |
| Modulation of Triglyceride Metabolism by Diet and Drugs | p. 107 |
| Reverse Cholesterol Transport - Regulation of Cholesterol Metabolism to Bile Acids | |
| Drugs Affecting Reverse Cholesterol Transport | p. 115 |
| High Density Lipoproteins: Function in Reverse Cholesterol Transport and Maintenance of Cellular Integrity | p. 121 |
| The Expression and Regulation of Cholesterol 7[alpha]-Hydroxylase | p. 131 |
| Cholesterol Metabolism in Normo and Genetically Hyperlipidemic Rats in Aging | p. 139 |
| LP(A) | |
| In Vitro Effect of Thiol- and Cysteine-Containing Compounds on the Immunological Reactivity of Human and Rhesus Monkey Lipoprotein(a) | p. 145 |
| The Interaction of Lp(a) with Liver Cells: Implications for Lipid Lowering Therapy | p. 151 |
| Metabolism of Apo(a) and ApoB-100 in Human Lipoprotein(a) | p. 161 |
| Antioxidants, Lipoproteins and AtherosclerosisX | |
| Vitamin E-Absorption, Transport in Lipoproteins, Delivery to Tissues and Antioxidant Activity | p. 169 |
| Role of the Macrophage Scavenger Receptor in the 9-Hydroxy-Octadecadienoic Acid Mediated Expression of Interleukin 1[beta] | p. 175 |
| Oxidative Damage to Circulating LDL | p. 183 |
| Drugs Affecting Atherosclerosis and Thrombosis | |
| Dietary Advice for the Prevention of Arterial Thrombosis | p. 191 |
| Drugs Affecting High-Density Lipoprotein and Triglyceride Metabolism | p. 199 |
| Drugs Affecting Thrombosis and Atherosclerosis | p. 215 |
| Lipid Lowering: Progression and Regression of Atherosclerotic Lesions | p. 231 |
| Clinical Trials of Atherosclerosis Regression | p. 241 |
| Biochemical Mechanisms Associated with the Lipolytic Effects of Calcium Channel Blockers | p. 251 |
| New Aspects of Hypolipidemic Therapy | |
| Pravastatin Reduces Plasma Concentration of a More Electronegatively Charged LDL Subfraction in FH | p. 261 |
| Clinical Experience with Flavastatin, the First Synthetic HMG-CoA Reductase Inhibitor | p. 269 |
| Secondary Prevention of Cardiovascular Disease: The Role of HMG-CoA Reductase Inhibitors | p. 277 |
| Combined Drug Treatment of Severe Hypercholesterolemia | p. 283 |
| Regression of Coronary Atherosclerosis by LDL-Apheresis | p. 293 |
| Partial Ileal Bypass - Results of the Program on the Surgical Control of the Hyperlipidemias (POSCH) | p. 299 |
| Hypercholesterolemia: Negotiating the Issues | p. 309 |
| Antiatherosclerotic Drugs: A Critical Assessment | p. 317 |
| HDL and Atherosclerosis | |
| Experimental and Clinical Evidence for a Protective Role of High-Density Lipoprotein in Coronary Heart Disease | p. 333 |
| HDL as a Risk Factor for Coronary Heart Disease: An Update on the Helsinki Heart Study | p. 339 |
| Relationship of HDL Cholesterol to Incidence of Atherosclerotic Coronary Heart Disease: The PROCAM Experience | p. 343 |
| The Clinical Approach to the Patients with Low HDL and Elevated Plasma Triglyceride | p. 357 |
| Atherosclerosis: A Multifactorial Approach | |
| Familial Lipoprotein Disorders in Patients with Premature Coronary Artery Disease | p. 365 |
| Efficacy of Fenofibrate on Plasma Cholesterol in Swine with Spontaneous Hypercholesterolemia | p. 375 |
| Lipoprotein Particles Heterogeneity: Clinical and Pharmacological Implication | p. 383 |
| Fibrinogen: Pathogenetical and Therapeutical Implications in Atherosclerosis | p. 391 |
| Regression and Decrease in Progression of Coronary Artery Disease Through Lipid-Lowering Therapy | p. 399 |
| Antioxidants and Lipid Metabolism: New Directions in the Management of Atherosclerosis and Hyperlipidemia | |
| Glycation and Oxidation of Proteins: A Role in the Pathogenesis of Atherosclerosis? | p. 407 |
| A Modern View of Atherogenesis | p. 421 |
| Defective Catabolism of Oxidized LDL by J774 Murine Macrophages | p. 427 |
| Analysis of Lipid vs. Non-Lipid Effect on Atherosclerosis Development | p. 441 |
| Triglyceride Rich Lipoproteins: Atherogenesis and Hemostasis | |
| Atherogenicity of Triglyceride-Rich Lipoproteins: Cellular Aspects | p. 447 |
| Atherogenicity of Triglyceride-Rich Lipoproteins: Clinical Aspects | p. 453 |
| Factors Influencing the Altered Lipoprotein System in Hypertriglyceridemia | p. 467 |
| Effects of Fibrates on the Altered Lipoprotein System in Hypertriglyceridemia | p. 477 |
| Triglyceride-Rich Lipoprotein: Role in Atherogenesis and Haemostasis | p. 483 |
| HDL, Phospholipids and Atherosclerosis | |
| The Role of Plasma Membrane Cholesterol Pools in the Regulation of Cellular Cholesterol Efflux | p. 493 |
| Kinetics of Exogenous Di-Linoleyl Phosphatidylcholine and Incorporation in Plasma and RBC Lipids in Man | p. 499 |
| Alimentary Lipemia and Phospholipids | p. 507 |
| Index | p. 515 |
| Table of Contents provided by Blackwell. All Rights Reserved. |
